163 related articles for article (PubMed ID: 18285440)
21. [Surrogate and true endpoints in cancer clinical trials].
Nakajima T; Ohta K; Ohyama S; Yamaguchi T
Gan To Kagaku Ryoho; 2000 May; 27(5):671-5. PubMed ID: 10832433
[TBL] [Abstract][Full Text] [Related]
22. Does the decision in a validation process of a surrogate endpoint change with level of significance of treatment effect? A proposal on validation of surrogate endpoints.
Sertdemir Y; Burgut R
Contemp Clin Trials; 2009 Jan; 30(1):8-12. PubMed ID: 18809512
[TBL] [Abstract][Full Text] [Related]
23. Bayesian adjusted R2 for the meta-analytic evaluation of surrogate time-to-event endpoints in clinical trials.
Renfro LA; Shi Q; Sargent DJ; Carlin BP
Stat Med; 2012 Apr; 31(8):743-61. PubMed ID: 22161275
[TBL] [Abstract][Full Text] [Related]
24. Alternative methods to evaluate trial level surrogacy.
Abrahantes JC; Shkedy Z; Molenberghs G
Clin Trials; 2008; 5(3):194-208. PubMed ID: 18559408
[TBL] [Abstract][Full Text] [Related]
25. Validation of surrogate markers in multiple randomized clinical trials with repeated measurements: canonical correlation approach.
Alonso A; Geys H; Molenberghs G; Kenward MG; Vangeneugden T
Biometrics; 2004 Dec; 60(4):845-53. PubMed ID: 15606404
[TBL] [Abstract][Full Text] [Related]
26. Evaluating time to cancer recurrence as a surrogate marker for survival from an information theory perspective.
Alonso A; Molenberghs G
Stat Methods Med Res; 2008 Oct; 17(5):497-504. PubMed ID: 18285443
[TBL] [Abstract][Full Text] [Related]
27. Interim futility analysis with intermediate endpoints.
Goldman B; LeBlanc M; Crowley J
Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
[TBL] [Abstract][Full Text] [Related]
28. [Surrogate endpoints].
Hill C
Bull Cancer; 1999; 86(7-8):622-4. PubMed ID: 10477379
[TBL] [Abstract][Full Text] [Related]
29. A statistical model for the dependence between progression-free survival and overall survival.
Fleischer F; Gaschler-Markefski B; Bluhmki E
Stat Med; 2009 Sep; 28(21):2669-86. PubMed ID: 19579225
[TBL] [Abstract][Full Text] [Related]
30. Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer?
Amir E; Seruga B; Kwong R; Tannock IF; Ocaña A
Eur J Cancer; 2012 Feb; 48(3):385-8. PubMed ID: 22115991
[TBL] [Abstract][Full Text] [Related]
31. Microbiologic surrogate end points in clinical trials of infectious diseases: example of acute otitis media trials.
Powers JH
Pharmacotherapy; 2005 Dec; 25(12 Pt 2):109S-123S. PubMed ID: 16305280
[TBL] [Abstract][Full Text] [Related]
32. Endpoints for assessing drug activity in clinical trials.
Pazdur R
Oncologist; 2008; 13 Suppl 2():19-21. PubMed ID: 18434634
[TBL] [Abstract][Full Text] [Related]
33. LDL-cholesterol differences predicted survival benefit in statin trials by the surrogate threshold effect (STE).
Johnson KR; Freemantle N; Anthony DM; Lassere MN
J Clin Epidemiol; 2009 Mar; 62(3):328-36. PubMed ID: 18834708
[TBL] [Abstract][Full Text] [Related]
34. Assessing surrogates as trial endpoints using mixed models.
Korn EL; Albert PS; McShane LM
Stat Med; 2005 Jan; 24(2):163-82. PubMed ID: 15515150
[TBL] [Abstract][Full Text] [Related]
35. Sensitivity analysis of progression-free survival with dependent withdrawal.
Ruan PK; Gray RJ
Stat Med; 2008 Apr; 27(8):1180-98. PubMed ID: 17768718
[TBL] [Abstract][Full Text] [Related]
36. Prognostic impact of extracellular matrix metalloprotease inducer: immunohistochemical analyses of colorectal tumors and immunocytochemical screening of disseminated tumor cells in bone marrow from patients with gastrointestinal cancer.
Buergy D; Fuchs T; Kambakamba P; Mudduluru G; Maurer G; Post S; Tang Y; Nakada MT; Yan L; Allgayer H
Cancer; 2009 Oct; 115(20):4667-78. PubMed ID: 19569245
[TBL] [Abstract][Full Text] [Related]
37. Surrogate marker evaluation from an information theory perspective.
Alonso A; Molenberghs G
Biometrics; 2007 Mar; 63(1):180-6. PubMed ID: 17447943
[TBL] [Abstract][Full Text] [Related]
38. Choosing the best endpoint.
Christensen E
J Hepatol; 2008 Oct; 49(4):672-3. PubMed ID: 18718690
[TBL] [Abstract][Full Text] [Related]
39. A unifying approach for surrogate marker validation based on Prentice's criteria.
Alonso A; Molenberghs G; Geys H; Buyse M; Vangeneugden T
Stat Med; 2006 Jan; 25(2):205-21. PubMed ID: 16220497
[TBL] [Abstract][Full Text] [Related]
40. Information-theory based surrogate marker evaluation from several randomized clinical trials with continuous true and binary surrogate endpoints.
Pryseley A; Tilahun A; Alonso A; Molenberghs G
Clin Trials; 2007; 4(6):587-97. PubMed ID: 18042568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
